Clinical Trial Detail

NCT ID NCT02626455
Title Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Bayer
Indications

lymphoplasmacytic lymphoma

follicular lymphoma

marginal zone B-cell lymphoma

CLL/SLL

Therapies

Vincristine Sulfate

Prednisone

Aldoxorubicin + Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate

Copanlisib

Bendamustine + Rituximab

Rituximab

Age Groups: adult

No variant requirements are available.